Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a collaboration agreement between the institute and Evotec. The partners will combine their platforms and expertise to develop antibiotics against resistant pathogens that pose an increasing threat to public health. They will first focus on cystobactamids, a promising group of natural antibiotic agents active against the most dangerous gram-negative bacteria on the WHO priority list.
The project will benefit from the partners’ complementary technology and know-how. The HZI provides access to its unique collection of natural products and in-vitro and in-vivo models of bacterial infection, while Evotec contributes its leading drug discovery platform, medicinal chemistry and pharmacology expertise and its world-leading collection of bacterial pathogens. The collaboration will initially run for three years.
Further information: See press release